Logo image of ALCJ.PA

CROSSJECT (ALCJ.PA) Stock Fundamental Analysis

EPA:ALCJ - Euronext Paris - Matif - FR0011716265 - Common Stock - Currency: EUR

1.5  -0.01 (-0.92%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ALCJ. ALCJ was compared to 58 industry peers in the Health Care Equipment & Supplies industry. ALCJ has a bad profitability rating. Also its financial health evaluation is rather negative. ALCJ is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALCJ has reported negative net income.
In the past year ALCJ has reported a negative cash flow from operations.
ALCJ had negative earnings in each of the past 5 years.
In the past 5 years ALCJ always reported negative operating cash flow.
ALCJ.PA Yearly Net Income VS EBIT VS OCF VS FCFALCJ.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -40.53%, ALCJ is doing worse than 81.03% of the companies in the same industry.
With a Return On Equity value of -470.75%, ALCJ is not doing good in the industry: 84.48% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -40.53%
ROE -470.75%
ROIC N/A
ROA(3y)-34.88%
ROA(5y)-33.65%
ROE(3y)-354.28%
ROE(5y)-361.76%
ROIC(3y)N/A
ROIC(5y)N/A
ALCJ.PA Yearly ROA, ROE, ROICALCJ.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALCJ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALCJ.PA Yearly Profit, Operating, Gross MarginsALCJ.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

1

2. Health

2.1 Basic Checks

ALCJ does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALCJ has more shares outstanding
Compared to 5 years ago, ALCJ has more shares outstanding
ALCJ has a worse debt/assets ratio than last year.
ALCJ.PA Yearly Shares OutstandingALCJ.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ALCJ.PA Yearly Total Debt VS Total AssetsALCJ.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

ALCJ has an Altman-Z score of -0.36. This is a bad value and indicates that ALCJ is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.36, ALCJ is not doing good in the industry: 75.86% of the companies in the same industry are doing better.
A Debt/Equity ratio of 6.53 is on the high side and indicates that ALCJ has dependencies on debt financing.
The Debt to Equity ratio of ALCJ (6.53) is worse than 86.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 6.53
Debt/FCF N/A
Altman-Z -0.36
ROIC/WACCN/A
WACC7.09%
ALCJ.PA Yearly LT Debt VS Equity VS FCFALCJ.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 1.66 indicates that ALCJ should not have too much problems paying its short term obligations.
ALCJ has a Current ratio (1.66) which is comparable to the rest of the industry.
A Quick Ratio of 1.08 indicates that ALCJ should not have too much problems paying its short term obligations.
ALCJ has a Quick ratio (1.08) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.08
ALCJ.PA Yearly Current Assets VS Current LiabilitesALCJ.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

3

3. Growth

3.1 Past

ALCJ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -23.99%.
ALCJ shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-23.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.65%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

ALCJ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 64.52% yearly.
The Revenue is expected to grow by 98.55% on average over the next years. This is a very strong growth
EPS Next Y163.92%
EPS Next 2Y104.3%
EPS Next 3Y64.52%
EPS Next 5YN/A
Revenue Next Year308.97%
Revenue Next 2Y140.35%
Revenue Next 3Y98.55%
Revenue Next 5YN/A

3.3 Evolution

ALCJ.PA Yearly Revenue VS EstimatesALCJ.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
ALCJ.PA Yearly EPS VS EstimatesALCJ.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ALCJ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
ALCJ is valuated reasonably with a Price/Forward Earnings ratio of 8.89.
94.83% of the companies in the same industry are more expensive than ALCJ, based on the Price/Forward Earnings ratio.
ALCJ is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.49, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 8.89
ALCJ.PA Price Earnings VS Forward Price EarningsALCJ.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALCJ.PA Per share dataALCJ.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2

4.3 Compensation for Growth

ALCJ's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ALCJ's earnings are expected to grow with 64.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y104.3%
EPS Next 3Y64.52%

More info and screens

0

5. Dividend

5.1 Amount

ALCJ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CROSSJECT

EPA:ALCJ (6/27/2025, 7:00:00 PM)

1.5

-0.01 (-0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-31 2025-03-31/amc
Earnings (Next)09-22 2025-09-22
Inst Owners0.56%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap69.34M
Analysts84.44
Price Target3.86 (157.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.74%
PT rev (3m)-6.59%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-51.18%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.89
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 25.51
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)0.17
Fwd EY11.24%
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0
BVpS0.06
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.53%
ROE -470.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.88%
ROA(5y)-33.65%
ROE(3y)-354.28%
ROE(5y)-361.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 6.53
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 67.57%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.08
Altman-Z -0.36
F-Score3
WACC7.09%
ROIC/WACCN/A
Cap/Depr(3y)131.18%
Cap/Depr(5y)130.12%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-23.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.65%
EPS Next Y163.92%
EPS Next 2Y104.3%
EPS Next 3Y64.52%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year308.97%
Revenue Next 2Y140.35%
Revenue Next 3Y98.55%
Revenue Next 5YN/A
EBIT growth 1Y-9.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year289.89%
EBIT Next 3Y71.59%
EBIT Next 5YN/A
FCF growth 1Y8.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.35%
OCF growth 3YN/A
OCF growth 5YN/A